scholarly journals Immunotoxin: A new tool for cancer therapy

Tumor Biology ◽  
2017 ◽  
Vol 39 (2) ◽  
pp. 101042831769222 ◽  
Author(s):  
Hossein Allahyari ◽  
Sahar Heidari ◽  
Mehdi Ghamgosha ◽  
Parvaneh Saffarian ◽  
Jafar Amani

Cancer is one of the main reasons of death in the most countries and in Iran. Immunotherapy quickly became one of the best methods of cancer treatment, along with chemotherapy and radiation. “Immunotoxin Therapy” is a promising way of cancer therapy that is mentioned in this field. Immunotoxins are made from a toxin attaching to an antibody target proteins present on cancer cells. The first-generation immunotoxins were made of a full-length toxin attached to whole monoclonal antibodies. But, these immunotoxins could bind to normal cells. DAB389IL2 was the first immunotoxin approved by the Food and Drug Administration. Current trends and researches are ongoing on finding proteins that in combination with immunotoxins have minimal immunogenicity and the most potency for target cell killing.

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Jinliang Gao ◽  
Tao Luo ◽  
Jinke Wang

AbstractAlthough some effective therapies have been available for cancer, it still poses a great threat to human health and life due to its drug resistance and low response in patients. Here, we develop a ferroptosis-based therapy by combining iron nanoparticles and cancer-specific gene interference. The expression of two iron metabolic genes (FPN and LCN2) was selectively knocked down in cancer cells by Cas13a or microRNA controlled by a NF-κB-specific promoter. Cells were simultaneously treated by iron nanoparticles. As a result, a significant ferroptosis was induced in a wide variety of cancer cells. However, the same treatment had little effect on normal cells. By transferring genes with adeno-associated virus and iron nanoparticles, the significant tumor growth inhibition and durable cure were obtained in mice with the therapy. In this work, we thus show a cancer therapy based on gene interference-enhanced ferroptosis.


2012 ◽  
Vol 2012 ◽  
pp. 1-13 ◽  
Author(s):  
Zhiyu Wang ◽  
Neng Wang ◽  
Jianping Chen ◽  
Jiangang Shen

Molecular-targeted therapy has been developed for cancer chemoprevention and treatment. Cancer cells have different metabolic properties from normal cells. Normal cells mostly rely upon the process of mitochondrial oxidative phosphorylation to produce energy whereas cancer cells have developed an altered metabolism that allows them to sustain higher proliferation rates. Cancer cells could predominantly produce energy by glycolysis even in the presence of oxygen. This alternative metabolic characteristic is known as the “Warburg Effect.” Although the exact mechanisms underlying the Warburg effect are unclear, recent progress indicates that glycolytic pathway of cancer cells could be a critical target for drug discovery. With a long history in cancer treatment, traditional Chinese medicine (TCM) is recognized as a valuable source for seeking bioactive anticancer compounds. A great progress has been made to identify active compounds from herbal medicine targeting on glycolysis for cancer treatment. Herein, we provide an overall picture of the current understanding of the molecular targets in the cancer glycolytic pathway and reviewed active compounds from Chinese herbal medicine with the potentials to inhibit the metabolic targets for cancer treatment. Combination of TCM with conventional therapies will provide an attractive strategy for improving clinical outcome in cancer treatment.


2015 ◽  
Author(s):  
Michael D. Forrest

ABSTRACTI use the Nernst equation, parameterised with experimental data, to predict that cancer cells will accumulate more of a lipophilic anion than normal cells. This effect is correlated to charge number. Model cancer cells accumulate *100 more of an anion, *103 more di-anion, *106 more tri-anion, *108 more tetra-anion and *1010 more penta-anion (>>1 billion times more). The trend endures, conveying even greater specificity, for higher charge numbers. This effect could be leveraged for cancer therapy. Wherein the lipophilic anion is a toxin that targets some vital cellular process, which normal and cancer cells may even share. It delivers a high, lethal dose to cancer cells but a low, safe dose to normal cells. This mathematical finding conveys the prospect of a broad, powerful new front against cancer.


2016 ◽  
Vol 1 (3) ◽  
Author(s):  
Teresa L. Wargasetia

MicroRNAs (miRNAs) are involved in the signaling circuits regulation within a cell andtheir deregulation plays an important role in cancer development and progression. In thisreview, we discussed miRNA biogenesis, miRNA function and the effect of miRNA abnormalitiesin cellular pathways that led to transformation of normal cells into cancer cells, as well as theindication of miRNAs as diagnostic and prognostic biomarkers of various types of cancer, asbiomarkers to predict the response to cancer therapy and the potential for development ofmiRNAs as cancer targeted therapy.Keywords: miRNA, cancer, diagnostic biomarker, prognostic biomarker, cancer therapy


2019 ◽  
Vol 19 (5) ◽  
pp. 580-586 ◽  
Author(s):  
Izabela Łasiñska ◽  
Jacek Mackiewicz

:Despite the great progress in the development of targeted therapies for different types of cancer utilizing monoclonal antibodies (e.g., cetuximab for colorectal cancer and head and neck cancer therapy), kinase inhibitors (e.g., sorafenib for kidney cancer and gastrointestinal stromal tumours therapy), and immunomodulatory treatments (e.g., nivolumab and pembrolizumab for melanoma therapy and lung cancer therapy), there is still a need to search for new, more effective treatments.:Integrins are responsible for intercellular adhesion and interaction with the cellular matrix. The function of integrins is related to the transduction of intracellular signals associated with adhesion, migration, cell proliferation, differentiation, and apoptosis. Molecules targeting integrins that lead to cancer cell death have been developed. The most advanced molecules studied in clinical trials are abituzumab, intetumumab and cilengitide. There are different groups of anti-integrin drugs: monoclonal antibodies (e.g., abituzumab) and other such as cilengitide, E7820 and MK-0429. These drugs have been evaluated in various cancer types. However, they have shown modest efficacy, and none of them have yet been approved for cancer treatment. Studies have shown that patient selection using biomarkers might improve the efficacy of anti-integrin cancer treatment. Many preclinical models have demonstrated promising results using integrin visualization for cancer detection and treatment efficacy monitoring; however, these strategies require further evaluation in humans.


Author(s):  
Anne-Marie Sapse

Cancer is an extraordinarily complicated group of diseases which are characterized by the loss of normal control of the maintenance of cellular organization in the tissues. It is still not completely understood how much of the disease is of genetic, viral, or environmental origin. The result, however, is that cancer cells possess growth advantages over normal cells, a reality which damages the host by local pressure effects, destruction of tissues, and secondary systemic effects. As such, a goal of cancer therapy is the destruction of cancer cells via chemotherapeutic agents or radiation. Since the late 1940s, when Farber treated leukemia with methotrexate, cancer therapy with cytotoxic drugs made enormous progress. Chemotherapy is usually integrated with other treatments such as surgery, radiotherapy, and immunotherapy, and it is clear that post-surgery, it is effective with solid tumors. This is due to the fact that only systemic therapy can attack micrometastases. The rationale for using chemotherapy is the control of tumor-cell populations via a killing mechanism. The major problem in this approach is the lack of selectivity of chemotherapeutic agents. Some agents indeed preferentially kill cancer cells, but no agents have been synthesized yet which kill only cancer cells and do not affect normal cells. Unfortunately, normal tissues are affected, giving rise to a multitude of side effects. In addition to drugs exhibiting cytotoxic activity, antiproliferative drugs are also formulated. According to their mode of action, anti-cancer drugs are divided into several classes. . . . alkylating agents antimetabolites DNA intercalators mitotic inhibitors lexitropsins drugs which bind covalently to DNA . . . Experimental studies of these molecules are complemented and enhanced by theoretical studies. Some of the theoretical studies use molecular mechanics methods while others apply ab initio or semi-empirical quantum-chemistry methods. Most of these molecules are large and besides their structures and properties it is important to investigate their interaction with DNA fragments (themselves large molecules). Ab initio calculations cannot always be applied to the whole system. Therefore, models are used and through a judicious choice of the entities investigated, the calculations can shed light on the problem and provide enough information to complement the experimental studies.


PEDIATRICS ◽  
1991 ◽  
Vol 88 (3) ◽  
pp. 552-552
Author(s):  
J. F. L.

Two competitors, Centocor Inc. and Xoma Corp., are seeking clearance from the Food and Drug Administration for an entirely new sort of anti-infection drug... The new drugs, unlike antibiotics that act upon the bacteria, latch on to toxins made by the bacteria, thus blocking the next biochemical step in the disease process. Both drugs are monoclonal antibodies, proteins that zero in on selected targets in the body. Centoxin is derived from human spleen cells; Xoma's drug, called Xomen E-5, from mouse spleen cells. ... Some estimates... put the combined U.S. and European sales for both drugs at $750 million by the mid-1990s. One reason for the jumbo market projections is sky-high prices for drugs produced by biotechnology. Centoxin and Xomen-E5 both are expected to cost between $1,500 and $2,500 for a single course of treatment, given by injection.


2020 ◽  
Vol 12 (15) ◽  
pp. 17276-17289
Author(s):  
Joanna Pilch ◽  
Edyta Matysiak-Brynda ◽  
Agata Kowalczyk ◽  
Piotr Bujak ◽  
Zofia Mazerska ◽  
...  

2020 ◽  
Vol 21 (18) ◽  
pp. 6684
Author(s):  
Samuele Lodovichi ◽  
Tiziana Cervelli ◽  
Achille Pellicioli ◽  
Alvaro Galli

Alterations in DNA repair pathways are one of the main drivers of cancer insurgence. Nevertheless, cancer cells are more susceptible to DNA damage than normal cells and they rely on specific functional repair pathways to survive. Thanks to advances in genome sequencing, we now have a better idea of which genes are mutated in specific cancers and this prompted the development of inhibitors targeting DNA repair players involved in pathways essential for cancer cells survival. Currently, the pivotal concept is that combining the inhibition of mechanisms on which cancer cells viability depends is the most promising way to treat tumorigenesis. Numerous inhibitors have been developed and for many of them, efficacy has been demonstrated either alone or in combination with chemo or radiotherapy. In this review, we will analyze the principal pathways involved in cell cycle checkpoint and DNA repair focusing on how their alterations could predispose to cancer, then we will explore the inhibitors developed or in development specifically targeting different proteins involved in each pathway, underscoring the rationale behind their usage and how their combination and/or exploitation as adjuvants to classic therapies could help in patients clinical outcome.


2017 ◽  
Vol 5 (1) ◽  
pp. 96-112
Author(s):  
Jerzy Kawiak ◽  
Grazyna Hoser ◽  
Joanna Domagała-Kulawik

SummaryHere we present the concept of making own patient’s anti-cancer treatment more efficient and starting at testing the efficacy of immunological system. The respective tests are suggested, with special attention devoted to tumour-induced microenvironmental changes. The tumour should be considered to represent a complex tissue in which the cancer cells communicate directly and indirectly with the surrounding cellular immunological surrounding and develope traits that promote their own survival. The results of tests allow to propose a rational, individually profiled treatment of a patient, especially directed to elimination of blocks inhibiting the immunological system due to effects of cancer cells. The elimination can be implemented using commercially available antibodies, targeted at the cell surface receptors for inhibitors of T lymphocytes (CTLA-4 and PD-1). Outcome of the therapy is slow to appear and the results used to be selective. Some patients gain long term improvement and respective predictive markers are now tested. It is assumed that the future anti-cancer therapy will be individually targeted, based on individual tests and an assistance of own immunological system of the cancer patient.


Sign in / Sign up

Export Citation Format

Share Document